Osterweis Capital Management’s AbbVie ABBV Stock Holding History

Osterweis Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.4M	Buy	107,478 +103,727	+2,765%	+$23M	1.21%	36
2025 Q4	$857K	Buy	3,751 +17	+0.5%	+$3.87K	0.04%	107
2025 Q3	$865K	Sell	3,734 -1,806	-33%	-$368K	0.04%	105
2025 Q2	$1.03M	Buy	5,540 +1,219	+28%	+$227K	0.05%	103
2025 Q1	$905K	Buy	4,321 +15	+0.3%	+$2.92K	0.04%	101
2024 Q4	$765K	Sell	4,306 -20	-0.5%	-$3.68K	0.04%	111
2024 Q3	$854K	Sell	4,326 -75	-2%	-$14K	0.04%	108
2024 Q2	$755K	Sell	4,401 -470	-10%	-$77.9K	0.04%	109
2024 Q1	$887K	Sell	4,871 -45	-0.9%	-$7.75K	0.05%	98
2023 Q4	$762K	Hold	4,916	–	–	0.05%	101
2023 Q3	$733K	Sell	4,916 -75	-2%	-$11K	0.05%	100
2023 Q2	$672K	Sell	4,991 -130	-3%	-$19.1K	0.04%	108
2023 Q1	$816K	Sell	5,121 -255	-5%	-$39K	0.06%	109
2022 Q4	$869K	Hold	5,376	–	–	0.06%	108
2022 Q3	$722K	Hold	5,376	–	–	0.05%	108
2022 Q2	$823K	Buy	5,376 +2,365	+79%	+$361K	0.06%	110
2022 Q1	$488K	Hold	3,011	–	–	0.03%	125
2021 Q4	$408K	Hold	3,011	–	–	0.02%	121
2021 Q3	$325K	Hold	3,011	–	–	0.02%	128
2021 Q2	$339K	Hold	3,011	–	–	0.02%	130
2021 Q1	$326K	Sell	3,011 -350	-10%	-$37.4K	0.02%	124
2020 Q4	$360K	Buy	+3,361	New	+$323K	0.02%	111
2019 Q2	–	Sell	-2,715	Closed	-$219K	–	106
2019 Q1	$219K	Hold	2,715	–	–	0.01%	104
2018 Q4	$251K	Hold	2,715	–	–	0.02%	94
2018 Q3	$256K	Hold	2,715	–	–	0.02%	104
2018 Q2	$251K	Sell	2,715 -955	-26%	-$93.3K	0.02%	103
2018 Q1	$348K	Hold	3,670	–	–	0.02%	99
2017 Q4	$355K	Hold	3,670	–	–	0.03%	96
2017 Q3	$326K	Hold	3,670	–	–	0.02%	96
2017 Q2	$266K	Hold	3,670	–	–	0.02%	93
2017 Q1	$239K	Sell	3,670 -1,000	-21%	-$62.9K	0.02%	88
2016 Q4	$292K	Hold	4,670	–	–	0.02%	82
2016 Q3	$295K	Sell	4,670 -45	-1%	-$2.91K	0.02%	83
2016 Q2	$292K	Sell	4,715 -75	-2%	-$4.57K	0.02%	79
2016 Q1	$274K	Buy	4,790 +1,165	+32%	+$64.9K	0.02%	76
2015 Q4	$215K	Sell	3,625 -1,305	-26%	-$75.2K	0.02%	47
2015 Q3	$268K	Sell	4,930 -105	-2%	-$6.83K	0.01%	56
2015 Q2	$339K	Sell	5,035 -50	-1%	-$3.26K	0.01%	60
2015 Q1	$297K	Hold	5,085	–	–	0.01%	58
2014 Q4	$333K	Sell	5,085 -115	-2%	-$7.25K	0.01%	61
2014 Q3	$300K	Buy	5,200 +1,000	+24%	+$55.5K	0.01%	63
2014 Q2	$237K	Sell	4,200 -130	-3%	-$6.82K	0.01%	62
2014 Q1	$223K	Hold	4,330	–	–	0.01%	66
2013 Q4	$228K	Hold	4,330	–	–	0.01%	73
2013 Q3	$210K	Hold	4,330	–	–	0.01%	70
2013 Q2	$179K	Buy	+4,330	New	+$189K	0.01%	73

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osterweis Capital Management's ABBV Position: Q1 2026 in Review

Osterweis Capital Management increased its AbbVie (ABBV) stake by 2,765% in Q1 2026, buying an estimated $23M and bringing the position to 107,478 shares worth $23.4M. The position accounts for 1.21% of the portfolio, ranked #36.

Osterweis Capital Management first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Osterweis Capital Management held 107,478 shares of AbbVie worth $23.4M as of Q1 2026.
Osterweis Capital Management bought 103,727 AbbVie shares in Q1 2026, an estimated $23M.
AbbVie made up 1.21% of Osterweis Capital Management's portfolio in Q1 2026, its #36 holding.
Osterweis Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Osterweis Capital Management's 13F filing for Q1 2026, filed 15 May 2026.